Advanced BioDesign unveils ABD0171, a novel ALDH1 inhibitor with potent ALDH1A3 selectivity, showing selective cytotoxicity against aggressive basal-like breast cancers, including TNBC, and other high-need epithelial subtypes. This novel compound expands the therapeutic potential of ALDH inhibition to additional hard-to-treat tumors.
This progress stems from multidisciplinary collaborations with Jaume Farrés (Universitat Autònoma de Barcelona), Rocio Rebollido-Rios (University of Cologne), Dr. Guy Fournet (Université Claude Bernard Lyon 1), and Bassam Janji (PhD, HDR) (Luxembourg Institute of Health along with their teams.
